Literature DB >> 15083486

Modification of the sample size and the schedule of interim analyses in survival trials based on data inspections, by H. Schäfer and H.-H. Müller, Statistics in Medicine 2001; 20: 3741-3751.

P Bauer, M Posch.   

Abstract

Mesh：

Year:  2004        PMID： 15083486     DOI： 10.1002/sim.1759

Source DB:  PubMed          Journal:  Stat Med        ISSN： 0277-6715            Impact factor:   2.373


× No keyword cloud information.
  13 in total

1.  Point and interval estimation in two-stage adaptive designs with time to event data and biomarker-driven subpopulation selection.

Authors:  Peter K Kimani; Susan Todd; Lindsay A Renfro; Ekkehard Glimm; Josephine N Khan; John A Kairalla; Nigel Stallard
Journal:  Stat Med       Date:  2020-05-03       Impact factor: 2.373

2.  Sequential tests for non-proportional hazards data.

Authors:  Matthias Brückner; Werner Brannath
Journal:  Lifetime Data Anal       Date:  2016-03-11       Impact factor: 1.588

3.  Bias, Operational Bias, and Generalizability in Phase II/III Trials.

Authors:  Boris Freidlin; Edward L Korn; Jeffrey S Abrams
Journal:  J Clin Oncol       Date:  2018-04-26       Impact factor: 44.544

4.  Randomized phase II/III confirmatory treatment selection design with a change of survival end points: Statistical design of Radiation Therapy Oncology Group 1216.

Authors:  Qiang Ed Zhang; Qian Wu; Paul M Harari; David I Rosenthal
Journal:  Head Neck       Date:  2018-12-14       Impact factor: 3.147

5.  Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls.

Authors:  Peter Bauer; Frank Bretz; Vladimir Dragalin; Franz König; Gernot Wassmer
Journal:  Stat Med       Date:  2015-03-16       Impact factor: 2.373

Review 6.  Adaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines Agency.

Authors:  Amelie Elsäßer; Jan Regnstrom; Thorsten Vetter; Franz Koenig; Robert James Hemmings; Martina Greco; Marisa Papaluca-Amati; Martin Posch
Journal:  Trials       Date:  2014-10-02       Impact factor: 2.279

7.  Optimizing the data combination rule for seamless phase II/III clinical trials.

Authors:  Lisa V Hampson; Christopher Jennison
Journal:  Stat Med       Date:  2014-10-15       Impact factor: 2.373

8.  Sample Size Reassessment and Hypothesis Testing in Adaptive Survival Trials.

Authors:  Dominic Magirr; Thomas Jaki; Franz Koenig; Martin Posch
Journal:  PLoS One       Date:  2016-02-10       Impact factor: 3.240

Review 9.  Methods for identification and confirmation of targeted subgroups in clinical trials: A systematic review.

Authors:  Thomas Ondra; Alex Dmitrienko; Tim Friede; Alexandra Graf; Frank Miller; Nigel Stallard; Martin Posch
Journal:  J Biopharm Stat       Date:  2016       Impact factor: 1.051

10.  Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency.

Authors:  Olivier Collignon; Franz Koenig; Armin Koch; Robert James Hemmings; Frank Pétavy; Agnès Saint-Raymond; Marisa Papaluca-Amati; Martin Posch
Journal:  Trials       Date:  2018-11-20       Impact factor: 2.279
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.